Indium-111-labeled B72. 3 monoclonal antibody in the detection and staging of breast cancer: A phase 1 study

Journal Article · Mon Jul 01 00:00:00 EDT 1991 · Journal of Nuclear Medicine; (United States)

OSTI ID:5392722

Lamki, L M; Buzdar, A U; Singletary, S E; Rosenblum, M G; Bhadkamkar, V; Esparza, L; Podoloff, D A; Zukiwski, A; Hortobagyi, G N; Murray, J L ^[1]

---

1. Department of Nuclear Medicine, University of Texas M.D. Anderson Cancer Center, Houston (USA)

Sixteen patients with primary breast cancer were studied with a pancarcinoma monoclonal antibody B72.3, an IgG1 molecule directed against tumor-associated glycoprotein (TAG-72) present in several tumors. Five millicuries of 111In was used to label 0.2 mg (six patients), or 2 mg (six patients), or 20 mg using the site-directed bifunctional DTPA method (at carbohydrate moiety). Digital, planar, and SPECT images were obtained at 2, 48, 72 and 96 hr when possible. HAMA levels were obtained before the Mab infusion and at 1, 3, and 6 wk postinfusion. Fourteen of 14 known primary breast lesions were detected by imaging (100% sensitivity). Two fibrocystic lesions were negative. Seven of 14 patients had lymph node metastases by histologic methods, but all were missed by radioimmunoscintigraphy. Tumor uptake of Mab ranged 0.00054%-0.0038% of the ID/g. The tumor-to-normal breast tissue ratio was 4.3 {plus minus} 0.91 (mean {plus minus} s.e.m.). Lymph nodes localization of 111In-B72.3 by tissue analysis was similar for tumor-bearing and normal nodes (0.0039 {plus minus} 0.0023 versus 0.0025 {plus minus} 0.0019). Pharmacokinetics revealed mean plasma half-life of 33.3-41.2 hr for the different doses. There was no statistical difference between any of the pharmacokinetic parameters of different doses. HAMA was positive only in 17% of the patients. The study suggests that this antibody has 100% sensitivity for primary breast cancers, but very poor detection rate of metastatic lesions in axillary lymph nodes; thus making it of questionable value in the initial staging process of this disease.

• OSTI ID: 5392722
• Journal Information: Journal of Nuclear Medicine; (United States), Vol. 32:7; ISSN 0161-5505
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MAMMARY GLANDS
NEOPLASMS
MONOCLONAL ANTIBODIES
LABELLING
DIAGNOSIS
RADIOIMMUNOSCINTIGRAPHY
SENSITIVITY ANALYSIS
BIOLOGICAL HALF-LIFE
DTPA
GLYCOPROTEINS
INDIUM 111
PATIENTS
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY
AMINO ACIDS
ANTIBODIES
BETA DECAY RADIOISOTOPES
BODY
CARBOXYLIC ACIDS
CHELATING AGENTS
COMPUTERIZED TOMOGRAPHY
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DIAGNOSTIC TECHNIQUES
DISEASES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
EMISSION COMPUTED TOMOGRAPHY
GLANDS
INDIUM ISOTOPES
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
MINUTES LIVING RADIOISOTOPES
NUCLEI
ODD-EVEN NUCLEI
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANS
PROTEINS
RADIOIMMUNODETECTION
RADIOISOTOPE SCANNING
RADIOISOTOPES
RADIOPROTECTIVE SUBSTANCES
SCINTISCANNING
TOMOGRAPHY
TRACER TECHNIQUES
550601* - Medicine- Unsealed Radionuclides in Diagnostics